Search

everythinglearnresearchcommunity

for

Search:↓

New treatments for excessive hair growth in women, including advanced drugs and nanotechnology, show promise for better results.

Oncologists should better understand the unique impact of hair loss on Black breast cancer patients to offer more compassionate care.

Cyproterone acetate with estradiol may subjectively improve excessive hair growth in women, but it's not clinically better than other treatments.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

ZD1839 can cause skin issues like acne and hair changes.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Norgestimate is the most effective birth control progestin for reducing an enzyme linked to acne and excessive hair growth in women.

Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

Antiandrogen therapy is effective and well tolerated for treating women's androgenic disorders like hirsutism, acne, and hair loss.

COVID-19 affects patients on chemotherapy for gynecological cancer negatively.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.

Androgens increase cervical cancer risk and affect its development.

ATR04-484 ointment shows promise for treating skin issues from cancer therapies.

Anastrozole can cause increased testosterone, leading to symptoms like hair growth and thinning.

Green-synthesized nanoparticles can effectively target cancer cells, reducing side effects and improving treatment.

Women's acne improvement with antibiotics is not linked to signs of high male hormones.

New anti-acne medications are being tested to offer alternatives to current treatments.

Women with androgenetic alopecia have normal levels of most blood steroids and binding proteins, but higher dehydroepiandrosterone. Some also have low "sex hormone-binding globulin" and "corticosteroide-binding globulin" capacity, and high "free androgen index" and "free cortisol index". Diane treatment can normalize these levels and improve hair conditions.

Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.

Propylthiouracil treatment can cause hair loss.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Cyproterone acetate is a safe treatment that causes mild feminizing effects and is more effective with added estrogens.

Dermatological treatments can have significant side effects, including allergic reactions, sexual dysfunction, and increased cancer risk.

Alpha mangostin may protect certain breast cancer cells by activating the p53 pathway.

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

Itraconazole effectively treated a woman's painful skin condition and hair loss.

Nanoparticles offer significant benefits over traditional chemotherapy for cancer treatment.